Understanding the immune memory and tracking variant immunity to the SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) is vital for improving the continuous diagnosis and enhancing treatment in form of vaccines for any future outbreaks.
Monitoring the variant immunity for SARS-CoV-2 spike protein, the experts agree that the pandemic isn’t over yet, and with infections ticking up now and then, there are new variants that have the potential to spin the immune systems.
The US and Canadian researchers’ study gives the conclusion that antibodies generated in vaccinated people and for recovered patients from SARS-CoV-2 spike protein, before 2022, cannot sustain the variants circulating in the world now.
The researchers have their expectations on the tool developed for antibody test which measures immunity, shall be regarded as a valuable tool to detect which community of people require the booster and when will the adequate time be to escape future lockdowns and save maximum lives in case of a spike.
With several antibody tests being developed and incorporated into the market over the three years, there are very few that are authorized and designed to closely monitor neutralizing antibodies. These help in detecting which coat the virus is wrapped in, and thus can give a solution by which it cannot bind or enter the host cell.
The distinction of the viral coat isn’t a cakewalk and it has critical importance, as there is only some part of SARS-CoV-2 spike protein antibodies that are generated while neutralizing. Though most vaccines are designed specifically for the SARS-CoV-2 spike protein to produce neutralizing antibodies, there is a question on how much they work on the variants.
A thorough understanding of immune memory of SARS-CoV-2 spike protein requires definitive evaluation of different components, such as B cells, CD8+ T Cells, and CD4+ T Cells. These are different cell times that may have the immune memory kinetics and are solemnly independent of each other.
There are complexities of immune memory and at the same time, SARS-CoV-2 spike protein has insights that prove the protective immunity against reinfection in a patient. The study pokes light on the immune memory branches. The three branches of adaptive immunity which has CD4+ T Cell, CD8+ T Cell, and humoral immunity.
“There will be new variants in the near future for sure”, Stagljar said. GeNext Genomics believes in the potential of antibody library and the SARS-CoV-2 spike protein, which has allowed us to keep in rigorous practice in developing potential biologics that can help in an outbreak. We keep monitoring and striving to boost immunity when it comes to the recombinant antibody library variations, which can increase the key role of biologics in the spike of the near future.
With a team of expert scientists, skilled researchers, and trained professionals, GeNext Genomics takes pride in developing and delivering services with efficacy to the pharmaceutical industry for vaccine development. We also develop high-quality chimeric antibody and several other biologics which help in better research and development practices against SARS-CoV-2 spike protein.